Megan Garlapow, PhD

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.

All articles by Megan Garlapow, PhD

Dominican heritage may raise risk of hereditary ATTR-CM variant

A genetic variant linked to ATTR-CM was more common in Hispanic individuals with more African ancestry, especially Dominican descent.
Pairing GLP-1 receptor agonists with SGLT2 inhibitors lowers risk of death in ATTR-CM

Patients with ATTR-CM who took both GLP-1RA and SGLT2i had lower death rates and fewer heart events than those on SGLT2i alone.
ATTR-CM may contribute to death in patients with Alzheimer’s disease

Cardiac transthyretin amyloidosis (ATTR-CM) was found in 12% of patients with Alzheimer’s disease and heart enlargement after death.
Exercise training improves function and quality of life in heart failure

Tailored exercise programs can reduce symptoms and improve quality of life in patients with HFpEF, including those with ATTR-CM.
Survey insights emphasize need to improve life with amyloidosis

Patients with amyloidosis, including ATTR-CM, value longevity, affordability and symptom relief above all.
New study urges broader screening for underrecognized ATTR-CM

One-third of patients diagnosed with ATTR-CM had normal heart wall thickness, suggesting current screening may miss early-stage cases.
RNAi therapies show promise for heart complications in ATTR-CM

RNAi therapies may reduce heart-related complications in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
New review explores benefits from recent advances in ATTR-CM treatment options

Tafamidis and acoramidis reduce mortality and improve quality of life for many patients living with ATTR-CM.
Early spinal surgery may indicate future ATTR-CM

Sixteen percent of patients developed transthyretin amyloid cardiomyopathy (ATTR-CM) within six years of surgery for lumbar spinal stenosis.
Addressing disparities in ATTR-CM diagnosis and treatment key for better care

Barriers to care in ATTR-CM include disparities in diagnosis, treatment access, and awareness among medical professionals.

Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

The ATTR-CM Journey